The tweet was deleted by the author.
But we saved everything 🙂.
Biomea Fusion is actively expanding its network at the BIO International Convention this week, connecting with industry colleagues, collaborators, and innovators from around the global biotechnology sector.
The company aims to leverage these meetings to exchange ideas, cultivate new relationships, and explore emerging business opportunities. The focus on forging strategic partnerships and staying engaged with the broader scientific community reflects Biomea Fusion's commitment to advancing its position within the competitive biotech landscape.
Earlier this year, Biomea Fusion visited clinical study sites to advance Phase II trials of icovamenib for type 2 diabetes, according to a company update. At the ADA2026 event, the team highlighted principal themes of innovation and research in diabetes care, as reported in a recent summary. These activities reinforce the company’s ongoing engagement across both research and industry events.